Short Interest in VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Expands By 88.9%

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 3,385,220 shares, a growth of 88.9% from the December 15th total of 1,791,894 shares. Approximately 8.8% of the shares of the company are short sold. Based on an average daily volume of 10,198,793 shares, the days-to-cover ratio is presently 0.3 days. Based on an average daily volume of 10,198,793 shares, the days-to-cover ratio is presently 0.3 days. Approximately 8.8% of the shares of the company are short sold.

Institutional Trading of VistaGen Therapeutics

Hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new position in VistaGen Therapeutics in the first quarter valued at $25,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of VistaGen Therapeutics during the 3rd quarter worth about $39,000. Millennium Management LLC bought a new stake in shares of VistaGen Therapeutics during the third quarter worth approximately $73,000. Bank of America Corp DE increased its position in VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after buying an additional 19,331 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in VistaGen Therapeutics in the 3rd quarter worth about $112,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on VTGN shares. Maxim Group restated a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Jefferies Financial Group reiterated a “hold” rating and issued a $0.90 target price (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. William Blair reissued a “market perform” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Wall Street Zen downgraded VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $0.95.

VistaGen Therapeutics Trading Up 2.3%

NASDAQ VTGN opened at $0.70 on Thursday. The company has a 50 day moving average of $2.79 and a 200-day moving average of $3.09. VistaGen Therapeutics has a 1-year low of $0.63 and a 1-year high of $5.14. The firm has a market cap of $27.71 million, a price-to-earnings ratio of -0.37 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.16 million. On average, analysts forecast that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.